Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Investigation on the Safety of Avocado Pulp Lipids

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03898505
Recruitment Status : Completed
First Posted : April 2, 2019
Last Update Posted : April 3, 2019
Sponsor:
Collaborator:
Advanced Orthomolecular Research
Information provided by (Responsible Party):
Paul A. Spagnuolo, University of Guelph

Brief Summary:

Obesity and diabetes are a significant global burden and there is an immediate need for novel treatments and management strategies. Our laboratory determined that avocado derived 17 carbon polyhydroxylated fatty alcohols (PFAs) are inhibitors of fatty acid oxidation (FAO) that impart minimal toxicity in mice. FAO is altered in numerous disease states including obesity and diabetes. In these chronic diseases, excessive FAO in muscle and liver mitochondria cause metabolic overload and inefficiency which drives obesity-associated glucose intolerance and insulin insensitivity. The increased FAO that occurs in obese and diabetic individuals depletes several substrates and intermediates of the Krebs cycle, making them less efficient at using oxidative phosphorylation for energy, which can ultimately lead to glucose insensitivity and weight gain. For these reasons, inhibition of FAO is now an established therapeutic approach for the treatment of type II diabetes as reducing FAO: i) improves cellular metabolism to shift towards the more thermogenic oxidative phosphorylation and glycolysis, and ii) reduces hyperglycemia via inhibiting liver gluconeogenesis while improving glucose homeostasis.

In collaboration with an industry partner, Advanced Orthomolecular Research (AOR; Calgary, AB), the investigators have developed a supplement containing a blend of 17-carbon PFAs found inside a commercially available food grade avocado powder. The primary objective of this clinical trial is to determine if the avocado derived supplement is safe for oral consumption compared to a placebo-controlled group.


Condition or disease Intervention/treatment Phase
Obesity Avocado Overnutrition Nutritional Disorder Metabolic Disease Lipid Metabolism Disorders Dietary Supplement: AvoMax (Low Dose) Dietary Supplement: AvoMax (High Dose) Other: Placebo Early Phase 1

Detailed Description:
This is a single center, double-blind, placebo-controlled, randomized clinical trial. 30 healthy subjects are planned. After screening and recruitment, subjects will be randomly allocated to treatment groups (low dose avocado powder or high dose avocado powder) or placebo control group. Once recruitment, randomization, baseline measurements as well as treatment allocation is completed (on the first site visit), each subject will orally consume one scoop (30-35g of material) of the avocado supplement, blended in 12-16 ounces of a smoothie like diluent, once per day for 60 days. The placebo group will also consume one scoop (30-35g of material) containing only non-medicinal ingredients used in the test product. Primary and secondary endpoint evaluations will be taken at baseline (site visit 2), day 30 (site visit 3) and day 60 (site visit 4) at each of the 3 study site visits as well as via weekly telephone calls to participants. Total duration of subject participation will be 60 days. Total duration of the study is expected to be 61 days.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Clinical Investigation on the Safety of Avocado Pulp Lipids
Actual Study Start Date : November 24, 2017
Actual Primary Completion Date : June 25, 2018
Actual Study Completion Date : August 1, 2018

Arm Intervention/treatment
Placebo Comparator: Placebo
Placebo powder containing only non-medicinal ingredients used in the test product: Oryza sativa (rice) bran extract (65-70% w/w of total placebo formulation), sodium bicarbonate, rosemary extract, xylitol, silicon dioxide, microcrystalline cellulose, rice hull powder, strawberry flavour. Participants in the placebo group will ingest 1 scoop of the placebo material per day (30-35g). Placebo powder is to be dissolved/blended in 12-16 ounces of a smoothie like diluent (e.g., 2% milk (with or without lactose), soy milk, coconut milk, or fruit juice of the participant's choice) and consumed orally. Placebo will be consumed once per day for 60 days.
Other: Placebo
Placebo product is powder containing only non-medicinal ingredients used in the test product: Oryza sativa (rice) bran extract (65-70% w/w of total placebo formulation), sodium bicarbonate, rosemary extract, xylitol, silicon dioxide, microcrystalline cellulose, rice hull powder, strawberry flavour.

Experimental: Low Dose
All Participants randomized to the low dose group will be consuming food grade avocado pulp powder (AvoMax) that will deliver a 50 mg dose of bioactive polyhydroxylated fatty alcohols (PFAs), avocadyne and avocadene. Participants in the low dose group will ingest 1 scoop of this test product per day (30-35g). Low dose test product is to be dissolved/blended in 12-16 ounces of a smoothie like diluent (e.g., 2% milk (with or without lactose), soy milk, coconut milk, or fruit juice of the participant's choice) and consumed orally. Low dose test product will be consumed once per day for 60 days.
Dietary Supplement: AvoMax (Low Dose)
AvoMax (Low Dose) is a natural spray-dried avocado powder, which contains 50 mg of a combination of bioactive polyhydroxylated fatty alcohols (PFAs), avocadyne and avocadene.

Experimental: High Dose
All Participants randomized to the high dose group will be consuming food grade avocado pulp powder (AvoMax) that will deliver a 200 mg dose of bioactive polyhydroxylated fatty alcohols (PFAs), avocadyne and avocadene. Participants in the high dose group will ingest 1 scoop of this test product per day (30-35g). High dose test product is to be dissolved/blended in 12-16 ounces of a smoothie like diluent (e.g., 2% milk (with or without lactose), soy milk, coconut milk, or fruit juice of the participant's choice) and consumed orally. High dose test product will be consumed once per day for 60 days.
Dietary Supplement: AvoMax (High Dose)
AvoMax (High Dose) is a natural spray-dried avocado powder, which contains a total of 200 mg of a combination of bioactive polyhydroxylated fatty alcohols (PFAs), avocadyne and avocadene.




Primary Outcome Measures :
  1. Incidence and severity of Adverse Events (AE) [ Time Frame: During treatment period (Day 1 to Day 60) ]
    Number of treatment emergent adverse events according to CTCAE v5.0.


Secondary Outcome Measures :
  1. Hematology [ Time Frame: At screening and during treatment period (day 30 and day 60) ]
    Number of clinically relevant changes in hematology markers as assessed by: hematocrit (HCT), hemoglobin (Hb), red blood cell count (RBC), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), white blood cell count (WBC), differential blood count (neutrophils, lymphocytes, monocytes, eosinophils and basophils), reticulocytes absolute count, and mean platelet volume (MPV). Assessments will be performed at screening and during treatment period.

  2. Biochemistry [ Time Frame: At screening and during treatment period (day 30 and day 60) ]
    Number of clinically relevant changes in serum biochemistry. Enzymes: alanine transaminase, creatine phosphokinase. Substrates: bilirubin (total), creatinine. Assessments will be performed at screening and during treatment period.

  3. Glycated Hemoglobin (HbA1c) [ Time Frame: At screening and during treatment period (day 30 and day 60) ]
    Mean absolute glycated hemoglobin (HbA1c) change from baseline

  4. Body Weight [ Time Frame: At screening and during treatment period (day 30 and day 60) ]
    Mean absolute body weight change from baseline

  5. Body Mass Index (BMI) [ Time Frame: At screening and during treatment period (day 30 and day 60) ]
    Mean absolute body mass index (BMI) change from baseline



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • adults 18 to 60 years of age
  • includes non-pregnant, non-breastfeeding women on adequate birth control
  • stable body weight (BMI: 18.5-29.9)
  • written informed consent obtained from subject and ability for subject to comply with the requirements of the study.

Exclusion Criteria:

  • Pregnant or breastfeeding
  • History or presence of diabetes
  • History or presence of hypertension
  • History or presence of dyslipidemia
  • History or presence of major depressive disorders
  • History or presence of chronic liver disorders
  • History or presence of kidney disorders
  • History or presence of blood disorders
  • Previous bariatric surgery (or any major surgeries or medical procedures to be scheduled within the time frame of the study)
  • Use of medication that causes significant weight gain or loss
  • Allergies to or inhibitions consuming all three choices of: 2% lactose free milk, soy milk, or coconut milk
  • Allergies to any ingredients in the placebo/investigational product
  • Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03898505


Locations
Layout table for location information
Canada, Ontario
Fundamentals of Health Naturopathic Medicine Clinic
Waterloo, Ontario, Canada, N2L 6H6
Sponsors and Collaborators
University of Guelph
Advanced Orthomolecular Research
Investigators
Layout table for investigator information
Principal Investigator: Paul Spagnuolo, PhD University of Guelph
Study Chair: Mary M Warndl, MD Medical Monitor
Study Director: Kim Bretz, ND Fundamentals of Health Naturopathic Medicine Clinic
Study Director: Nawaz Ahmed, MSc University of Guelph

Layout table for additonal information
Responsible Party: Paul A. Spagnuolo, Associate Professor, University of Guelph
ClinicalTrials.gov Identifier: NCT03898505     History of Changes
Other Study ID Numbers: 232024
First Posted: April 2, 2019    Key Record Dates
Last Update Posted: April 3, 2019
Last Verified: April 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Paul A. Spagnuolo, University of Guelph:
Avocado
Polyhydroxylated Fatty Alcohols
Avocatin B

Additional relevant MeSH terms:
Layout table for MeSH terms
Disease
Metabolic Diseases
Lipid Metabolism Disorders
Overnutrition
Nutrition Disorders
Pathologic Processes
Ethanol
Anti-Infective Agents, Local
Anti-Infective Agents
Central Nervous System Depressants
Physiological Effects of Drugs